BLRX

BioLineRx Ltd

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd (BLRX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 1.1
Rev Growth YoY 87.1%
Gross Margin 79.2%
Price Return 3M -9.2%
Price Return 12M -28.7%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 8.9
ROE -46.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) B (3.4) B (3.4) C (2.4) C- (1.9) C+ (2.8)
2026-08-04 C+ (2.7) B (3.4) B (3.4) C (2.4) C- (1.9) C+ (2.8)
2026-08-03 C+ (2.7) C+ (2.7) B (3.3) C (2.4) C- (2.0) C+ (2.6)
2026-08-02 C+ (2.7) C+ (2.7) B (3.3) C (2.4) C- (1.9) C+ (2.6)